Vaxcell-Bio Therapeutics박셀바이오

Vaxcell-Bio remains deeply loss-making with a small, rising revenue base, and its shares are down sharply over the past year.

Vaxcell-Bio is a Korean cell-therapy and immunotherapy developer that also sells veterinary products and runs a drug distribution business. For the trailing twelve months to H1 2026 it reported revenue of about ₩6.5B against an operating loss of about ₩16.7B, and cash of about ₩5.6B against borrowings of about ₩1.7B. The share price closed at ₩4,125 on 2026-10-22, down 56.3% over one year, though it is roughly flat over three months.

What stands out

• Revenue rose sharply from ₩13.7M in 2023 to ₩1.9B in 2024 and ₩7.1B in 2025, but operating losses have stayed around ₩15B to ₩16B a year.
• The trailing operating margin is -257.1% and the net margin is -229.1%, so sales cover only a small part of costs.
• Free cash flow over the trailing period was about -₩17.4B, against cash of about ₩5.6B, which means the filings alone do not show how the gap is funded.
• The filings list a half-year report for June 2026, a quarterly report for March 2026 and an IR event in May 2026, but the data does not include pipeline milestones or trial timelines.
• Foreign ownership fell from 5.5% to 5.0% over 60 days, and the 20-day flows show net foreign selling of about ₩435M.
• The only news item in the data is a conference poster from another company, Theragen Bio, so there is no company-specific news in the pack.

What to watch

• Next quarterly or annual filings, to see whether revenue growth continues and whether the operating loss narrows.
• Cash runway: the data shows ₩5.6B of cash against ₩17.4B of negative free cash flow over the trailing period, and the data does not say how this will be financed.
• Any new financing, share issuance or changes in major shareholding, which are not described in the data.